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Background: The Rome IV criteria for disorders of gut- brain interaction define irri-








tween	 IBS	 and	 FC/FD,	 and	 the	 relative	 influence	 of	 abdominal	 pain	 frequency	 on	






vs.	 10%).	 Increasing	 abdominal	 pain	 frequency	 correlated	 positively	with	 PHQ-	12,	
number	of	 somatic	 symptoms,	 and	HADS;	p < 0.001. No differences in mood and 
somatization	 scores	were	 seen	between	 individual	 IBS	 subtypes,	 and	nor	between	
FC	and	FD.
Conclusion & Inferences: Based	on	 the	Rome	 IV	criteria,	 IBS	 is	associated	with	 in-
creased	 levels	of	psychological	distress	and	somatization	compared	with	FD	or	FC.	
Patients reporting frequent abdominal pain should be comprehensively screened for 
psychosomatic	disorders,	with	psychological	therapies	considered	early	in	the	disease	
course.
2 of 9  |     SHIHA et Al.
1  |  INTRODUC TION
Functional	bowel	disorders	belong	to	the	spectrum	of	disorders	of	
gut- brain interaction.1 They are defined as chronic lower gastroin-
testinal symptoms that occur in the absence of organic disease to 
explain the symptoms.1 Recent large- scale epidemiological studies 
report	functional	bowel	disorders	to	affect	1-	in-	4	adults,	 in	whom	
the vast majority are represented by either irritable bowel syndrome 
(IBS),	functional	constipation	(FC),	or	functional	diarrhea	(FD).2 The 
Rome	Foundation	has,	over	the	last	30	years,	provided	clinicians	and	
researchers with symptom- based criteria to aid toward the recogni-
tion of functional gastrointestinal disorders.3	As	of	May	2016,	 the	
Rome IV criteria was released which differs markedly from the pre-
vious Rome III iteration with regards to the diagnosis of IBS.4,5 The 
Rome IV criteria defines IBS as a functional bowel disorder associ-
ated	with	frequent	abdominal	pain	of	at	least	1	day	per	week,	which	
contrasts to the relatively lax Rome III criteria where a diagnosis of 
IBS was based on abdominal pain or discomfort at least 2– 3 day per 
month.4,5 This change in criteria has reduced the prevalence of IBS 
by	almost	half,	going	from	9.0%	under	Rome	III	to	4.6%	under	Rome	
IV.2 Those individuals no longer satisfying a diagnosis of IBS under 









interaction.1,3 While functional abdominal pain has historically been 
linked	with	mood	disturbances,6 a recent study comprising 100 pa-
tients found no difference in psychosomatic symptoms between pa-
tients	with	IBS-	D	and	FD	based	on	the	Rome	IV	criteria.7	However,	
this	 study	 evaluated	 the	 diarrhea	 subtypes	 only	 and,	 moreover,	
77%	of	patients	labeled	as	having	FD	were	experiencing	abdominal	
pain	(with	almost	40%	having	abdominal	pain	at	least	once	a	week)	
which questions whether they should have been classed as IBS- D 
instead.7	Elsewhere,	multiple	groups	have	shown	that	subjects	with	
Rome IV IBS have higher levels of psychological and somatic distress 
compared	with	those	who	do	not	meet	Rome	IV	criteria	for	IBS,	al-
though these studies have methodological limitations.8–	11	For	exam-
ple,	some	have	evaluated	datasets	of	Rome	III	defined	IBS	patients	
and	applied	a	surrogate	marker	to	identify,	or	rather	assume,	which	
patients	may	 or	may	 not	 have	 IBS	 under	 the	 Rome	 IV	 criteria,9,10 
whereas others have recruited online participants self- reporting IBS 
without verifying the diagnosis.11	Moreover,	those	subjects	deemed	
unlikely to have Rome IV IBS have not been distinctly defined as 
having	FD	or	FC,	but	rather	pooled	under	the	spectrum	of	any	other	
functional	 bowel	 disorder,	 thereby	 limiting	 our	 understanding	 of	
their particular disease subtype.8–	11
We therefore undertook a study to compare levels of psycho-
logical	distress	and	somatization	between	IBS	and	FC/FD	based	on	





2.1  |  Study design and participants
This prospective observational study took place at Sheffield 
Teaching	Hospitals,	United	Kingdom,	during	the	course	of	2019.	
All	 English-	speaking	 adults,	 aged	 18	 years	 and	 over,	 referred	 at	
the clinical discretion of their GI physician for an out- patient co-
lonoscopy (excluding those as part of the national bowel cancer 
screening program) were eligible to participate. Individuals were 
invited to self- complete a baseline questionnaire collecting de-
mographic and symptom- based data followed by undergoing a 
colonoscopy.





• The frequency of abdominal pain correlates positively with psychological distress and so-
matic co- morbidity.
•	 Patients	with	functional	bowel	disorders,	and	in	particular	those	who	report	abdominal	pain,	




    |  3 of 9SHIHA et Al.
2.2  |  Baseline questionnaire
The following items were collected prior to colonoscopy:
a.	 Demographic	 data—	participants	 entered	 their	 age,	 sex,	 and	
ethnicity.
b. Past gastrointestinal history— patients were asked whether they 




c.	 The	Hospital	 Anxiety	 and	Depression	 scale	 (HADS)12— this 14- 
item instrument contains seven questions for anxiety and seven 
questions	 for	depression.	Each	question	 is	 scored	 from	0	 to	3,	
providing a minimum score of 0 (no symptoms) and a maximum 
score	of	21	(maximal	severity	of	symptoms)	on	each	subscale.	A	
subscale	 score	of	≥11	 is	used	 to	 indicate	a	clinically	 significant	
level of anxiety or depression.
d. The Patient Health Questionnaire (PHQ)- 12 evaluates the se-
verity of extra- intestinal somatic symptoms. The twelve non- GI 
symptoms	assessed	are	back	pain,	limb	pain,	headaches,	chest	
pain,	 dizziness,	 fainting	 spells,	 palpitations,	 breathlessness,	
menstrual	 cramps,	 dyspareunia,	 insomnia,	 and	 lethargy.13 
Subjects were asked to rate how much they had been troubled 
by these twelve symptoms over the last four weeks as 0 (“not 
bothered	at	all”),	1	(“bothered	a	little”),	or	2	(“bothered	a	lot”).	






e. The Rome IV bowel disorder questionnaire14— this validated tool 
was used to identify patients who had symptoms compatible with 
one of the following functional bowel disorders; IBS and its sub-
types	(IBS-	constipation,	IBS-	diarrhea,	IBS-	mixed),	and	FD	and	FC.4 






completed questions on how frequently they experienced hard or 
lumpy	stools	 (type	1	or	2	on	the	Bristol	stool	form	scale),	strained	
with	defecation,	had	a	sensation	of	incomplete	evacuation,	and	per-





was the threshold used to define an abnormal frequency within the 
clinical setting.
2.3  |  Colonoscopy
The endoscopists performing the colonoscopies were blinded to the 
baseline	questionnaire	data.	A	normal	colonoscopy	was	defined	as	
no	endoscopic	and	histological	evidence	of	colon	cancer,	inflamma-
tory	 bowel	 disease,	 or	microscopic	 colitis.	We	 did	 not	 take	 diver-
ticulosis	 into	 consideration	 and,	 moreover,	 any	 association	 with	
functional bowel disorders is controversial.15
2.4  |  Definitions of functional bowel disorders
We have recently used this dataset to report on the diagnostic 
outcomes of colonoscopy in patients with symptoms compatible 
with a Rome IV functional bowel disorder.16	 For	 the	 purpose	 of	
the	 current	 study,	 a	 diagnosis	 of	 IBS,	 FC,	 or	 FD	was	 reached	 in	
those subjects with compatible symptoms (as per the Rome IV 
diagnostic questionnaire) and had a normal colonoscopy exami-
nation and a negative past gastrointestinal history. Patients not 
fulfilling this criteria were deemed not to have a functional bowel 
disorder. None of the patients had functional abdominal bloating/
distension.
2.5  |  Statistical analysis
The primary analysis compared differences in mood and soma-
tization	scores	between	Rome	 IV	 IBS	and	FC/FD,	and	 the	 relative	
influence of abdominal pain frequency on these extra- intestinal 
symptoms.	 However,	 prior	 to	 undertaking	 this	 main	 analysis,	 we	
compared	 difference	 in	 mood	 and	 somatization	 scores	 between	
those patients with and without a Rome IV functional bowel disor-
der. The secondary analysis evaluated differences across individual 
IBS	subtypes,	and	also	between	FC	and	FD.
Statistical	 analysis	 was	 carried	 out	 using	 SPSS	 version	 25.0	








multiple groups using 1- way analysis of variance. Correlations were 
assessed using Spearman's test.
2.6  |  Ethics
The study commenced following ethical approval by Sheffield 
Teaching	 Hospital	 (protocol	 number:	 STH20572)	 and	 the	 Health	
Research	Authority	(IRAS	project	ID:	253210).	The	study	was	con-
ducted in accordance with the STROBE statement. Patients who 
4 of 9  |     SHIHA et Al.
returned their questionnaire consented for their data to be used for 
analysis.
3  |  RESULTS
3.1  |  Study participants
We sent out 3000 questionnaires of which 1329 were returned with 







3.2  |  Comparison in demographic and symptom 
scores between subjects with and without a Rome IV 
functional bowel disorder
Patients with a Rome IV functional bowel disorder— compared 
to	 those	 without—	were	 significantly	 younger	 (mean	 age	 56	 vs.	
59	years,	p	<	0.001),	had	a	higher	female	representation	(62%	vs.	
48%,	p	<	0.001),	and	reported	greater	levels	of	psychological	dis-
tress	 and	 somatization	 (Table	 1).	 The	 increased	 associations	 for	
clinically	 abnormal	 levels	 of	 anxiety,	 depression,	 and	 moderate-	
high	 somatization	 scores	 seen	 in	 those	 with	 a	 functional	 bowel	
disorder persisted despite adjusting for age and gender; data not 
shown.





Rome IV FBDs 





Female	(%) 366	(48%) 349	(62%) <0.001




































Low 286	(37.5%) 199	(35%) <0.001
Medium 153	(20%) 180	(32%)
High 32	(4%) 59	(10.4%)





(n = 318) p- value
Demographics
Mean	age,	years	(SD) 61	(13) 51	(7) <0.001
Female	(%) 130	(52%) 219	(62%) <0.001























Mean PHQ- 12 
score (SD)
5.4	(3.4) 9.1 (4.2) <0.001
Number of somatic 
symptoms (SD)
4.3 (2.4) 6	(2.6) <0.001
Level	of	somatization	severity	(%)
Minimal 88	(35%) 41	(13%)
Low 90	(36%) 109	(34%) <0.001
Medium 64	(26%) 116	(36.5%)
High 7	(3%) 52	(16%)
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3.3  |  Comparison in demographic and symptom 
scores between Rome IV IBS and FC/FD
As	outlined	in	Table	2,	patients	with	IBS	were	significantly	younger	
than	those	with	FD/FC	(mean	age	51	years	vs.	61	years,	p < 0.001) 
and	 had	 a	 higher	 female	 predominance	 (62%	vs.	 52%,	p < 0.001). 
Furthermore,	 patients	 with	 IBS	 had	 a	 significantly	 higher	 HADS	
score	(15.0	vs.	11.7,	p	<	0.001),	and	clinically	abnormal	levels	of	anxi-





of the 12 items listed on the PHQ- 12 at a level of “bothered a lot” 






3.4  |  Comparison between IBS- D and FD, and 
between IBS- C and FC
Patients	with	 IBS-	D	were	younger,	had	a	greater	female	represen-
tation,	 experienced	 more	 psychosomatic	 distress,	 and	 reported	
increased	 stool	 urgency	 than	 those	 with	 FD	 (Table	 3).	 Following	
adjustments	 for	age,	gender,	and	bowel	habit,	patients	with	 IBS-	D	
were	more	likely	than	FD	to	have	abnormal	levels	of	anxiety	(AOR	
TA B L E  3 Comparison	of	basic	demographic	and	symptom	scores	
between	Rome	IV	IBS-	D	and	FD
IBS- D 
(n = 133) FD (n = 147) p- value
Mean-	age,	years	(SD) 52	(15.1) 60	(13.1) <0.001

























Number of somatic 
symptoms (SD)
5.9	(2.5) 4.2 (2.3) <0.001
Level	of	somatization	severity	(%)
Minimal 17	(13%) 55	(37%)







Urgency 114	(86%) 89	(60.5%) <0.001
TA B L E  4 Comparison	of	basic	demographic	and	symptom	scores	
between	Rome	IV	IBS-	C	and	FC.
































6.1	(2.4) 4.3 (2.3) <0.001
Level	of	somatization	severity	(%)
Minimal 6	(9%) 33	(32%)




Type 1– 2 hard/
lumpy stools
62	(92.5%) 73	(72%) 0.001




Manual digitation 23	(34%) 26	(25.5%) 0.22
6 of 9  |     SHIHA et Al.










We	 found	 no	 statistical	 differences	 in	mood	 and	 somatization	
symptom	scores	between	FC	and	FD,	 and	nor	between	 individual	
IBS subtypes (supplementary tables B/C).
3.5  |  Correlation between the frequency of 
abdominal pain and psychosomatic symptoms
Increasing abdominal pain frequency correlated positively with PHQ- 
12 score (r	=	0.4,	p	<	0.001),	number	of	somatic	symptoms	(r	=	0.37,	













Our findings are in keeping with systematic reviews reporting a 
high	prevalence	of	psychosomatic	distress	in	IBS	patients,17,18 with 
observational data showing this to occur to a greater extent than in 
FD	or	FC.19	However,	the	definition	of	IBS	in	these	studies	was	based	
on	historic	criteria,	such	as	the	Rome	I-	III	iterations,	which	were	far	
more accommodating and thus comprised a heterogeneous pool 
of patients compared with the stringent Rome IV criteria. Recent 
groups have since attempted to compare levels of psychosomatic 
distress	 in	 subjects	with	and	without	Rome	 IV	 IBS,	demonstrating	
conflicting results and with certain limitations related to patient se-
lection and functional bowel disorder classification.7–	11	In	contrast,	




The association between increasing abdominal pain frequency and 
psychosomatic distress is in line with a Swedish community- based sur-
vey which linked anxiety and depression to functional abdominal pain 
in both IBS patients and healthy subjects.6 Combined with our own 
findings,	this	suggests	the	need	to	consider	adopting	different	clinical	
and	therapeutic	strategies	between	Rome	IV	IBS	and	FC/FD.	Firstly,	
patients with IBS— and in particular those experiencing frequent ab-
dominal pain— should be routinely screened for psychological ill- health 
and	 somatic	 symptoms,	 and	 not	 just	 bowel-	related	 symptoms.	 This	
concept would be supported by the Rome committee who advocate a 
multidimensional	clinical	profile	approach	to	help	characterize	the	full	
breadth of the patient's illness state.3	Secondly,	as	somatic	symptom	
reporting in IBS is independently associated with increased rates of un-
necessary	surgical	interventions,	clinicians	must	be	wary	of	this	link	to	
prevent its occurrence.20,21	Thirdly,	studies	should	consider	evaluating	
F I G U R E  1 Prevalence	of	different	
levels	of	PHQ-	12	somatization	among	
patients with Rome IV functional bowel 
disorders according to the frequency of 
abdominal pain
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the	 role	of	psychological	 therapies	 (ie,	 neuromodulators	 and	behav-
ioral	psychotherapy)	earlier	in	the	treatment	paradigm	for	IBS,	as	op-
posed to them being reserved for individuals refractory to standard 
gut-	directed	or	peripherally	acting	therapies	(eg,	antispasmodics,	laxa-
tives,	diet	etc).	The	National	Institute	of	Health	and	Clinical	Excellence	
currently recommend psychological therapies for patients who remain 
symptomatic following medical treatment but only after 12 months 
have	elapsed,	although	evidence	to	support	this	approach	is	sparse.22 
Psychological therapies exert their beneficial effects via the release 
of	 neurotransmitters	 leading	 to	 changes	 in	 visceral	 hypersensitivity,	
neuroplasticity,	pain	modulation,	and	mood.23 They have been shown 
to be among the most effective strategies for IBS with a number 
needed to treat of 4.24,25	Moreover,	a	recent	network	meta-	analysis	
of	randomized	controlled	trials	(of	soluble	fiber,	antispasmodic	drugs,	
peppermint	oil,	and	gut-	brain	neuromodulators	for	IBS)	ranked	tricyclic	
antidepressants first for efficacy when abdominal pain was used as the 
outcome measure.26	Finally,	integrating	psychological	therapy	within	a	
multidisciplinary clinical care package is superior to gastroenterologist- 
only	 care	 in	 relation	 to	 symptoms,	 psychological	 state,	 quality	 of	
life,	and	cost	of	care	for	the	treatment	of	functional	gastrointestinal	
F I G U R E  2 Prevalence	of	abnormal	
levels	of	clinical	(A)	anxiety	and	(B)	
depression among patients with Rome IV 
functional bowel disorders according to 
the frequency of abdominal pain
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disorders.27	Hence,	there	is	growing	support	for	earlier	deployment	of	
psychological	 therapies	within	 functional	 gut	disorders,	 in	particular	
for	 IBS,	although	a	 limiting	 factor	has	historically	been	attributed	to	
a lack of familiarity with the use of neuromodulators among gastro-
enterologists,	and	the	practical	constraints	associated	with	delivering	
face- to- face behavioral psychotherapy over a prolonged time period 
within	a	busy	healthcare	service.	To	address	 these	 issues,	 there	has	
been	recent	guidance	from	the	Rome	Foundation	Working	Team	ed-
ucating and empowering gastroenterologists towards becoming com-
fortable with prescribing neuromodulators.23 There is also promising 
data	to	show	minimal-	contact	cognitive	behavioral	therapy,	which	par-
ticipants can self- administer at home via telephone or web (thereby 
reducing clinic service pressures) is efficacious at improving IBS symp-
toms and has sustained benefit at 24- month follow- up.28,29 Despite 
the	 data	 supporting	 the	 use	 of	 psychological	 therapies	 in	 IBS,	 it	 is	
worth highlighting that many clinical trials generally exclude patients 
with underlying psychological co- morbidities or fail to screen for them. 
Moreover,	they	tend	to	use	neuromodulators	at	low	doses	to	treat	ab-
dominal	pain	and	bowel	habit,	not	psychological	illnesses.	In	summary,	
given that an appreciable subset of patients with IBS under the Rome 
IV criteria have high levels of psychological distress and somatic co- 










able that levels of psychological distress may have been heightened 
due	 to	 the	presence	of	 alarm	 features,	 severe	 symptoms,	 and	 the	
concern	regarding	the	potential	endoscopic	diagnosis.	However,	this	
is unlikely to explain the difference in psychological distress and so-
matization	 seen	 between	 those	 subsequently	 diagnosed	with	 and	
without	a	functional	bowel	disorder,	and	between	Rome	IV	IBS	com-
pared	with	 FD	 or	 FC.	 Secondly,	 despite	 population-	based	 studies	
having previously demonstrated high levels of psychosomatic disor-
ders	in	community	subjects	with	IBS,6,17,18 our results should not be 
generalized	to	patients	managed	in	the	primary-	or	secondary-	care	
out-	patient	 clinic	 setting,	many	of	whom	will	be	a	younger	cohort	
with mild symptoms and no red flags to warrant a colonoscopy. 
Thirdly,	 while	 a	 colonoscopy	 excluded	 organic	 disease	 within	 the	
colon,	it	is	possible	that	subjects	with	diarrhea	may	have	had	coeliac	
disease or primary bile acid diarrhea which can account for roughly 
4%	and	25%	of	 cases,	 respectively,	 although	 testing	 for	 the	 latter	




and the association noted between IBS and psychosomatic distress 
cannot be evaluated further to identify the direction of causality. 
Previous studies have shown that in one- third of individuals a mood 
disorder	 precedes	 gut	 symptoms,	 but	 in	 two-	thirds	 gut	 symptoms	






research studies should consider evaluating the role of psychological 
therapies	early	in	the	disease	course	for	IBS,	while	evaluating	both	
bowel- and mental health- related end points.
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